Skip to Main Content

Author Details

Charles L Sawyers
Memorial Sloan Kettering Cancer Center
1986
286
123
PMIDPaper TitleJournal TitlePublished Year
36749798Macrophages promote anti-androgen resistance in prostate cancer bone disease.J Exp Med2023
37653066Addressing racial and ethnic disparities in AACR project GENIE.NPJ Precis Oncol2023
37502956NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer.bioRxiv2023
37531417Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.Sci Transl Med2023
37402365Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1.Mol Cell2023
35195258Understanding Drug Sensitivity and Tackling Resistance in Cancer.Cancer Res2022
35790797Author Correction: Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes.Nature2022
35447082Allosteric interactions prime androgen receptor dimerization and activation.Mol Cell2022
36590695An immunocompetent rectal cancer model to study radiation therapy.Cell Rep Methods2022
35952322Prospective Clinical Genomic Profiling of Ewing Sarcoma: <i>ERF</i> and <i>FGFR1</i> Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance.JCO Precis Oncol2022
35981096Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling.Science2022
34353917Rapid interrogation of cancer cell of origin through CRISPR editing.Proc Natl Acad Sci U S A2021
34417459Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.Nat Commun2021
32220301Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.Cancer Cell2020
32015092Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.Cancer Res2020
32888433FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.Cancer Cell2020
32679108Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.Cancer Cell2020
33015525Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer.JCO Precis Oncol2020
32755461Linked Entity Attribute Pair (LEAP): A Harmonization Framework for Data Pooling.JCO Clin Cancer Inform2020
32895534Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.Nature2020
32152485Lineage plasticity in cancer: a shared pathway of therapeutic resistance.Nat Rev Clin Oncol2020
32355025Regenerative potential of prostate luminal cells revealed by single-cell analysis.Science2020
32203275Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance.Nat Rev Clin Oncol2020
32376773Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis.Cancer Discov2020
32220959Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.Proc Natl Acad Sci U S A2020
30587545SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.Clin Cancer Res2019
31710046Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses.J Vis Exp2019
31243370FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.Nature2019
31519311Herceptin: A First Assault on Oncogenes that Launched a Revolution.Cell2019
31363002The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.Clin Cancer Res2019
31152158Publisher Correction: The long tail of oncogenic drivers in prostate cancer.Nat Genet2019
31061129Genomic correlates of clinical outcome in advanced prostate cancer.Proc Natl Acad Sci U S A2019
31171376Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2.Kidney Int2019
30312421Strategies to Identify and Target Cells of Origin in Prostate Cancer.J Natl Cancer Inst2019
30644358GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance.Elife2019
30589920Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.JAMA Oncol2019
29121144Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.JAMA Oncol2018
30179225Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
30178746Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.Elife2018
29921838Patient derived organoids to model rare prostate cancer phenotypes.Nat Commun2018
30109253Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer.Cell Mol Gastroenterol Hepatol2018
30652542American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives.JCO Clin Cancer Inform2018
30382943Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
29417929Challenges in validating candidate therapeutic targets in cancer.Elife2018
29610475The long tail of oncogenic drivers in prostate cancer.Nat Genet2018
29369701Targeting DNA Repair in Prostate Cancer.J Clin Oncol2018
29258679Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.Eur Urol2018
28059767Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.Science2017
28453708Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape.Ann Oncol2017
29057879Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis.Nat Commun2017
  • 1 - 50 of 286

Recommended Authors

Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 16
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 12
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 33
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 5
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 3
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 16
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 4
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 22
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Career Start Year 1996
Number of shared co-authors 3
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 19
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 7
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1993
Number of shared co-authors 10
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 22
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 1993
Number of shared co-authors 7
Barry R Davies
Oncology R&D
Career Start Year 1992
Number of shared co-authors 9
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 13
John Easton
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 9
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 23
Katherine Stemke-Hale
MD Anderson Cancer Center, University of Texas
Career Start Year 1989
Number of shared co-authors 7
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 12
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 7
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 21
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 14
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 51
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 1
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 3
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 20
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 59
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 4

Collaborators

Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 30
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Co-authored papers 23
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 21
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Co-authored papers 19
Neil P Shah
University of California San Francisco
Co-authored papers 16
Mark A Rubin
University of Bern
Co-authored papers 15
Anuradha Gopalan
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Co-authored papers 15
Owen N Witte
University of California los angeles
Co-authored papers 14
Brian J Druker
Oregon Health & Science University
Co-authored papers 13
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 12
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 12
Elisa de Stanchina
Co-authored papers 12
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 11
Michael J Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 10
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 10
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 10
Joshua Armenia
Oncology R&D
Co-authored papers 10
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Co-authored papers 10
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Co-authored papers 10
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 9
Moshe Talpaz
University of Michigan Rogel Cancer Center.
Co-authored papers 8
Dana E Rathkopf
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Victor E Reuter
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 8
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 8
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 8
Francesca Demichelis
University of Trento
Co-authored papers 8
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 8
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 8
Susana Miranda
The Institute of Cancer Research
Co-authored papers 7
Release 1.2